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Introduction 
This report presents responses to two series of questions that were raised by a subcommittee of the 
Nuclear Energy Research Advisory Committee (NERAC) that has been charged with producing a "Long- 
Term Isotope Research and Production Plan." The NERAC subcommittee is chaired by Dr. Richard 
Reba, and the Hanford Site Visit team, which comprises a subset of the subcommittee members, is 
chaired by Dr. Thomas Ruth. 
The first set of questions raised by the subcommittee on isotope production at the Hanford Site was 
received from Dr. Ruth on May 10, 1999, and the second set was received from him on July 5, 1999. 
Responses to the first set of questions were prepared as part of a June 1999 report entitled "Isotope 
Production at the Hanford Site in Richland, Washington" (PNNL 1999a). The responses to these 
questions are summarized in this document, with frequent references to the June 1999 report for 
additional details. Responses to the second set of questions from the NERAC subcommittee are 
presented in this document for the first time. 
1 Responses to the First Set of Questions 
The set of questions received on May 10, 1999, consisted of two broad questions, the first of which 
contained 10 individual questions to which responses are given below. 
1.0 How well does the Department's existing five-site production infrastructure 
serve the need for commercial and research isotopes? 
1 .I What is the physical condition of the isotope processing facilities and equipment? 
Response: 
The primary isotope production facilities at the Hanford Site are the Radiochemical Processing 
Laboratory (RPL) (Building 325 in the 300 Area of the Hanford Site) and the Fast Flux Test Facility 
(FFTF) reactor (in the 400 Area of the Hanford Site). In addition, there are several other laboratory 
facilities that are suitable for various aspects of target preparation and radiochemical processing of 
isotopes. These facilities are discussed briefly in this document, with reference to PNNL (1999a) for 
additional details. 
(a) RPL. The RPL is a 143,700 ft2 building that contains laboratories and specialized facilities designed 
for work with nonradioactive materials, microgram-to-kilogram quantities of fissionable materials, 
and up to megacurie quantities of other radionuclides. The total space occupied by general chemistry 
laboratories is 44,300 ft2, of which 6,950 ft2 (15.6%) is presently unoccupied. All of the occupied, 
and nearly all of the unoccupied laboratories are functional and fully equipped with standard utilities. 
Several of the laboratories, especially those used for radioanalytical work, have been renovated 
during the past few years. The upgrading and modernization of equipment within the chemistry 
laboratories has been given a high priority during the past two years. 
During a recent space utilization survey of the RPL, an assessment was made of the number of fume 
hoods and shielded glove boxes (including small hot cells) that are available for additional 
programmatic work. Of the 79 functional fume hoods and 23 shielded glove boxes, 50 and 15, 
respectively, are available for additional work. 
A special feature of the RPL is the existence of two heavily shielded facilities located in annexes on 
the East and West sides of the building. These shielded facilities are the High-Level Radiochemistry 
Facility (HLRF) and the Shielded Analytical Laboratory (SAL). These two hot cell complexes, 
which are heavily utilized at the present time, provide capabilities for conducting bench-scale to 
pilot-scale work with a wide variety of highly radioactive materials. Capabilities include those 
required to conduct radiochemical separation and purification procedures, irradiated fuel or target 
sectioning and processing, metallography, physical properties testing of activated metals, thermal 
processing (including waste vitrification), and radioanalytical and preparatory chemistry operations. 
The HLRF contains three large, interconnected hot cells designated as A-Cell, B-Cell, and C-Cell. 
The three cells are each 15 ft high and 7 ft deep; the A-Cell is 15 ft wide and the B-Cell and C-Cell 
are each 6 ft wide. In-cell operations are performed using medium-duty electromechanical 
manipulators, and the work is viewed through leaded-glass, oil-filled windows. The hot cells are 
equipped with television cameras, VCRs, overhead bridges,hoists, and standard utilities. They have 
shielded service penetrations at the front wall for insertion of special instrumentation. 
The SAL contains six interconnecting hot cells, each of which is 5.5 ft wide, 5.5 ft deep, and 9.5 ft 
high. Each hot cell is equipped with a pair of mediumduty manipulators. Turntables built into the 
rear walls of the hot cells provide rapid transfers of radioactive samples into and out of the cells. The 
SAL hot cells are equipped to perform a wide variety of analytical chemistry operations with highly 
radioactive samples. 
Additional information on the RPL, and its laboratory facilities that could be devoted to new isotope 
production missions in the future, is contained in PNNL (1999a) (Section 2.5.1). 
(b) FFTF. The FFTF's original mission was to support liquid-metal reactor technology development and 
reactor safety by providing fuels and materials irradiation services. Although the U.S. liquid-metal 
reactor program ended at about the same time, that the FFTF commenced operation in 1982, the 
reactor continued operation for 10 years as a national research facility to test advanced nuclear fuels 
and materials, nuclear power plant operating procedures, and active and passive reactor safety 
technologies. The facility was also used to produce more than 40 different radioisotopes for use in 
research, medicine, and industry. In addition, FFTF generated tritium for the U.S. fusion research 
program and supported cooperative, international nuclear research activities. The reactor was shut 
down in December 1993, and since that time has been in a standby operational condition, pending a 
decision by DOE on its future use. In May 1999, the Secretary of Energy announced that a special 
90-day study led by the Director of the Pacific Northwest National Laboratory, Dr. William Madia,. 
would be conducted to establish whether the FFTF should be considered for future missions related to 
national and international nuclear technology needs. The nuclear science and irradiation services 
provided by FFTF will focus on a core federal role of meeting multiple 21'' Century needs, including: 
1. providing a large and reliable supply of radioisotopes for research, medical, and industrial 
applications 
2. promoting safer nuclear technology through reactor safety testing and the development of 
proliferation-resistant nuclear fuels 
3. producing power sources for deep-space exploration through the production of plutonium-238 for 
radioisotope thermoelectric generators, and for research on compact space reactor technology 
4. sustaining the nuclear option for power production through testing of fuels, components, and 
reactor instrumentation 
5. conducting advanced research and providing services related to the testing of materials for fusion 
reactors, hardening and testing of materials such as semiconductors, and research on 
transmutation of nuclear waste materials. 
These future missions, and the business plan for FFTF's proposed future operations, are described in 
a document that will be submitted to NERAC on July 20, 1999 for review before submission to the 
Secretary of Energy on August 2, 1999. This document is entitled "Program Scoping Plan for the Fast 
Flux Test Facility: A Nuclear Science and Irradiation Services User FacilityW(PNNL 1999b).'") 
The FFTF consists of the reactor, which is capable of steady-state operation at a rated power level of 
400 MW, and several support buildings and equipment arranged around the central reactor containment 
building. Heat is removed from the reactor by liquid sodium that is circulated through three primary 
loops, which include the pumps, piping, and intermediate heat exchangers. During a total loss of power, 
the FFTF is designed to shut down automatically and the reactor will continue to be cooled by natural 
circulation of the sodium. An emergency power source consisting of batteries will provide essential plant 
monitoring capabilities in the event of a shutdown. The reactor also has safety features that can maintain 
cooling if a leak occurs in the liquid sodium heat transport system. 
Other major systems located in the FFlT reactor containment building are: 
the Closed Loop Ex-Vessel Handling Machine that is used to install fuel and target assemblies in the 
reactor and to remove them at the end of the irradiation cycle 
the Interim Examination and Maintenance ( E M )  Cell, in which an irradiated assembly is washed and 
dried to remove residual sodium before disassembly; the target pins are then removed from irradiated 
assemblies with manipulators and placed in containers for removal from the IEM cell 
a Bottom-Loading Transfer Cask, which is used to transfer the pin container from the reactor 
containment building to a cask loading station in the Reactor Service Building. 
Detailed descriptions and photographs of the FFTF containment building and the special facilities 
described above are contained in PNNL (1999a) (Section 2.5.2). 
(c) Other Available Facilities. In planning for a proposed future FFTF isotope production mission, 
several facilities at the Hanford Site have been examined as possible locations for target preparation 
and the processing of isotope products. In all cases, these facilities have desirable physical features 
and equipment that could make them useful if an expansion of facilities is required later to meet a 
growth in the demand for FFTF isotope products. Three candidate facilities are: 
(a) This document is referred to hereafter in this report as the "FFlT Scoping Plan." 
1. Building 306E. Located in the 300 Area of the Hanford Site, this facility has been used in the 
past to fabricate a variety of reactor components, fuel assemblies, and radioisotope target 
assemblies. Some of the target fabrication equipment and non-destructive examination 
equipment still exist in the building and are available for use. 
Postirradiation Testing Laboratory. Located in the 300 Area at the Hanford Site, this facility 
contains 13 hot cells and support laboratories for the physical and metallurgical examination of 
irradiated fuels, fission products, and irradiated structural materials. Decontamination of the hot 
cell facilities has been underway for two years, and is expected to be completed within the next 
two years. Only a small amount of programmatic work is currently being conducted, and a study 
on the long-range utilization of this facility is underway, including use by commercial companies 
under lease agreements. This alternative may be attractive for establishing long-term business 
relationships with companies interested in the preparation and processing of targets irradiated 
at FFTF. 
3. Maintenance and Storage Facility. Located in the 400 Area of the Hanford Site about 500 ft 
north of FFTF, this facility is a multi-purpose service center that supports the specialized 
maintenance and storage requirements of the FFW. A special feature of this facility is a large 
shielded enclosure that contains two shielded decontamination rooms that can be used for both 
remote and hands-on cleaning of equipment and tools. This facility, including the shielded 
enclosures, was not fully utilized during the ten years of full-scale FTTF operation, and 
consideration has been given to its possible use for the fabrication and disassembly of 
FFI'F targets. 
Additional details on each of these facilities are contained in PNNL (1999a) (Section 2.5.3). 
1.2 What capital investments are needed to ensure the near-term operability of the 
facilities? If additional resources are needed, are they practical (e.g., technically 
rational, easily integrated into existing infrastructure, quickly implemented and 
supportable)? Will any portion be sustainable over time by local financial and 
personnel resources? 
Response: 
As part of the planning activities for a future FFTF nuclear science and irradiation services mission, 
an estimate has been prepared of the costs associated with restarting the reactor for steady-state operations 
at a 100-MW power level. This estimate, expressed in FY 1999 dollars, is $229M. The capital 
expenditures are distributed over a four-year period from 2001 - 2004, and include funds for 
(1) recovering systems that were shut down before the standby decision in late 1993, (2) equipment and 
instrumentation upgrades, (3) fabrication of rapid radioisotope retrieval (R3) vehicles for removal of 
short-lived isotope targets while the reactor is at power, (4) modification of hot cells and support 
laboratories for target processing operations, and (5) staff increases and training. Once restarted, the 
estimated annual cost of FETF operations is $55M. A more detailed description of the schedule and costs 
for FFTF restart is provided in the FFTF Scoping Plan (PNNL 1999b). 
A business model has been developed as part of the FFTF Scoping Plan (PNNL 1999b) that 
incorporates plans for recovering approximately $100M of the restart costs over the projected 35-year 
operating life of the reactor. This business model was developed using the guidelines provided in DOE 
Order 21 10.1A, "Pricing of Department Materials and Services and DOE Implementing Guidance on 
Federal Administrative Charges." The model is comparable to those currently in use at other DOE 
reactor facilities, and has been reviewed and accepted by the DOE Chief Financial Officer in meetings 
held during June 1999. The FFTF business model provides adequate resources to ensure both the near- 
term and sustained future operability of the reactor. 
In this business model, the funding in FY 1999 dollars required during the reactor restart phase 
includes both the $229M discussed above and $55M in operating funds to maintain the FFTF's standby 
mode of operation during the period 2000-2001. During the projected 35-year operating lifetime of the 
reactor (2004-2038), a "value recovery charge" of -4% will be applied to all private-sector irradiation 
services. The funds recovered through this charge will be placed in an investment fund that is expected to 
grow at an annual rate estimated to be -5% above inflation, and thereby generate -$100M to offset a 
portion of the restart costs. 
The staffing infrastructure to support both the reactor operations and radiochemical processing of 
irradiated targets are in place and adaptable to rapid growth of the nuclear science and irradiation services 
components of the FFTF mission. As described in detail in the FFTF Scoping Plan and PNNL (1999a), 
the operations staff at the FFTF will increase from the current level of 260 full-time equivalent (FTE) to 
410 FTE at the time of restart. This increase will accommodate the full set of operational services 
required for target insertion, irradiation, and retrieval in the isotope production program. Target 
preparation is expected to be carried out by a subcontractor working in facilities at the Hanford Site. 
Radiochemical processing of the isotope targets will be carried out by members of the PNNL . 
Radiochemical Processing Group (RPG), which consists of 75 technical and administrative staff that 
occupy the RPL (described in PNNL (1999a), Section 2.4.1). The isotope production team within the 
RPG currently has 12 staff members, of which 5 perform radiochemical processing operations. It is 
expected that the number of scientists and technicians performing radiochemical operations will increase 
to 21 FTE at the time FFTF commences full operation. This expansion will be achieved by reassignment 
of radiochemists and technical support staff within the RPG, and by new hires. In addition to the staff 
involved in radiochemical processing operations, it is expected that the number of staff involved in 
packaging and shipping will increase from 0.5 FTE to 7.5 FTE, and that the marketing, sales and 
administrative staff will increase from 1.5 FTE to 5.5 FTE. 
Although the FFTF Scoping Plan (PNNL 1999b) does not explicitly include privatization of the 
reactor operations or the isotope production mission, discussions have been initiated with private-sector 
companies that may have an interest in commercializing various components of these operations (e.g., the 
marketing, sales, and distribution of isotope products). These discussions are expected to continue over 
the coming five-year period (i.e., during the preparation of the FFTF Environmental Impact Statement 
and the reactor restart activities), with a reasonable probability of success in establishing partnership 
agreements between DOE and commercial organizations. 
1.3 What is the availability of the primary nuclear facility (accelerator or reactor) over 
the next five years (e.g., HFlR outage, LANSCE program changes)? 
Response: 
If the current plans to initiate preparation of an Environmental Impact Statement in October, 1999 are 
met, then it is expected that FFTF will be restarted by July 2004. Details of the restart schedule are given 
in the FFI'F Scoping Plan (PNNL 1999b). In addition, all of the target preparation and processing 
facilities such as the RPL are expected to remain available for work in support of the FETF isotope 
production mission. 
1.4 What understanding exists at each site about the priority of isotope production to 
serve isotope customers? 
Response: 
Because many of the isotopes produced at the Hanford Site are shipped to customers at medical 
centers for the treatment of critically ill cancer patients, the isotope production program receives a very 
high priority. For example, the staff performing the radioanalytical work and on-site transportation 
services in support of the isotopes program give this work the highest priority among their multiple tasks. 
A complete radionuclide analysis and Inductively Coupled Plasma (ICP) analysis of the chemical purity 
of the isotopes sent to customers are performed within 24 hours of the completion of isotope production. 
These data are then sent immediately to the customer for review before use of the isotope. 
Another example of the high priority given to the medical isotopes program occurred five years ago 
when the FWL was shut down temporarily for safety upgrades. By direct order of the Manager of the 
DOE Richland Operations Office, Mr. John Wagoner, the production of yttrium-90 for medical customers 
was allowed to continue unintermpted during the entire shutdown period, which lasted about one year. 
1.5 How much influence does each site manager have in planning the use of multi- 
purpose facilities? 
Response: 
The Manager of the Hanford Radioisotopes Program, Dr. Thomas Tenforde, also serves as the lead 
scientist for the isotope production team within the RPG. The organizational structure and primary areas 
of research are described in PNNL (1999a) (Section 2.4.1). In his capacity as head of the isotope 
production team within the FWG, the manager of the Hanford Radioisotopes Program has line 
management responsibilities for the staff and facilities involved in the radiochemical processing of 
isotopes for commercial, medical, and research applications. These staff, together with a matrixed team 
of nuclear physicists, engineers, radiochemists, and nuclear safety specialists from PNNL and other 
Hanford contractor organizations, have functioned since 1997 as a support group for planning the 
proposed future FFTF isotope production mission. An important part of this planning has been the 
identification of laboratory facilities that will be given a high priority for future use in support of the 
FFTF isotope production mission. 
1.6 What cost-containment measures are being pursued? 
Response: 
Cost-containment efforts in the isotopes program are centered around the use of activity-based costing 
procedures for all isotope products. Following the costing procedures adopted by the DOE Office of 
Isotope Programs (NE-70), an annual costlprice analysis is performed on each isotope product using a 
four-level Work Breakdown Structure. Examples of this type of cost analysis are given in PNNL (1999a) 
(Section 2.6.1) and in the response given below to the first of the new set of questions received from the 
NERAC subcommittee on July 5, 1999. 
In all aspects of isotope production, efforts are made to streamline the radiochemical laboratory 
procedures and to use the most economical services available from various contractor organizations at the 
Hanford Site. For example, ICP analyses of the chemical purity of isotope products are performed at the 
222s Building under a subcontract with the Fluor Daniel Hanford Company, which is a less expensive 
option (by nearly a factor of 2) than performing these analyses in the RPL operated by PNNL. 
1.7 What licensing issues need to be addressed? 
Response: 
If a decision is made to restart the FFTF, it will be subject to all DOE requirements for the operation 
of a nuclear facility, as described under DOE Order 425.1A ("Startup and Restart of Nuclear Facilities," 
1995). Licensing of the FFTF under the regulations for commercial reactors will not be a regulatory 
requirement. However, it is expected that DOE will request the Nuclear Regulatory Commission to 
conduct a detailed technical review of the safety aspects of operating the facility, similar to the procedure 
that was followed prior to initial startup of the reactor in the early 1980s. In addition, the International 
Atomic Energy Agency (IAEA) may be requested to verify the inventory and characteristics of nuclear 
materials at the FFTF. The IAEA has declared its willingness to help facilitate FFTF's use by the 
international nuclear science community. 
It is the goal of the Hanford Radioisotopes Program to transfer technology for the production and 
applications of medical isotopes to the private sector through appropriate licensing agreements. A recent 
example is the licensing agreement signed by NEN Life Science Products, Inc., on October 12, 1998, to 
use PNNL's patented process for extracting yttrium-90 from a strontium-90 generator in a highly purified 
form. Under this license agreement, the management contractor organization for PNNL - the Battelle 
Memorial Institute - receives an initial fee of $75K and subsequent royalties based on a percentage of 
the net sales value of yttrium-90 sold by NEN. The estimated value of this agreement for Battelle is 
approximately $500K over a five-year license period. This licensing agreement was part of a broader 
commercialization effort in which NEN took over from PNIK all aspects of the production, marketing, 
sales, and distribution of yttrium-90 (described in more detail in PNNL (1999a), Section 2.2.2). 
Based on the success of the yttrium-90 privatization activity, PNNL is currently involved in efforts to 
commercialize other technology that has been developed for the medical application of radioisotopes. For 
example, negotiations are underway with a private company for use of PNNL's radioactive composite 
polymer delivery system for treating prostate tumors and other forms of cancer. 
In addition to technology licensing agreements, consideration has been given to establishing facility 
lease agreements under which commercial companies could perform work in DOE facilities at the 
Hanford Site. For example, a study is underway on the feasibility and opportunities for privatizing part or 
all of the Postirradiation Testing Laboratory described above in the response to Question 1 . l .  This 
facility, as well as other laboratories in the 300 Area of the Hanford Site, will be considered for use by 
private-sector companies in future work related to the preparation and processing of targets for FFTF 
isotope production. 
1.8 What unused or underused capacity (e.g., personnel, facilities) could be mobilized 
to support a growth in isotope demand? 
Response: 
As discussed above in the response to Question 1.1, a recent survey of space utilization in the RPL 
indicated that -7000 ft2 of functional laboratory space is currently available for radiochemical work in 
new projects. It is anticipated that reassignment of laboratory space within the RPL will be made in the 
future to accommodate the full set of requirements for the radiochemical processing of multiple FETF 
isotope targets. In addition, as also discussed above in the response to Question 1.2, there are extensive 
support facilities available for isotope target preparation and processing in Building 306E and in the 
Postirradiation Testing Laboratory at the Hanford Site. 
With regard to the availability of trained staff who could be mobilized in support of a growth in 
isotope demand, there are currently about five scientists and technicians within the 75-member RPG that 
could be utilized in that capacity (in addition to the staff that are members of the isotope production 
team). The overall workload and availability for new assignments of radiochemistry staff in the RPG is 
driven primarily by funding for work in support of the Hanford nuclear waste cleanup mission and the 
processing and disposal of nuclear fuels. As the time approaches for restart of the FFIF reactor in mid- 
2004, an assessment will be made of staff assignments to support the isotope production mission. It 
appears likely at this time that recruitment and hiring of new staff will be required during the year 
preceding restart of the FFTF. However, as indicated above in the response to Question 1.2, ongoing 
discussions with private-sector companies could lead to privatization of various components of the FETF 
isotope production program. The commercialization of various elements of work involved in the 
preparation, irradiation, and processing of isotope targets, as well as the marketing, sales, and distribution 
of the final isotope products, could have a significant impact on the staffing requirements that must be 
met by.PNNL and other contractor organizations at the Hanford Site involved in the FiFI"F isotope 
production mission. 
1.9 Summarize customer inquiries received during the past two years. What percent 
was filled, referred to other facilities, or rejected? Explain unfilled requests. 
Response: 
During the past two years the primary isotope product supplied by the Hanford Site has been 
yttrium-90. Weekly shipments of this medical isotope have been supplied to more than 40 customers who 
are using yttrium-90 primarily for cancer radioimmunotherapy. As described in PNNL (1999a) 
(Section 2.6.2), PNNL provided more than 1200 consecutive on-time shipments of yttrium-90 to 
DOE customers during the two-year period preceding the commercialization of this program. No orders 
were rejected and there were no unfilled requests for yttrium-90 over the past two years. 
Responses are also made to customer inquiries regarding isotopes that are not produced at the 
Hanford Site. These inquiries are answered within one work day by referring the customers to other DOE 
Isotope Production Sites or commercial suppliers. 
1.10 How does each site manager rate customer satisfaction for his site? For the 
overall program? 
Response: 
The level of satisfaction expressed by customers for isotope products supplied by the Hanford 
Radioisotopes Program has consistently been very high. Our dedication to customer service, as 
exemplified by the 100% on-time record for more than 1200 shipments of yttrium-90 over the past two 
years, has earned a number of compliments in letters sent by satisfied customers (summarized in PNNL 
(1999a), Section 2.6.2). In addition to the timeliness of isotope shipments, the staff involved in isotope 
production have received a number of compliments for the consistently high quality of isotope products 
produced at the Hanford Site. 
With regard to.the overall DOE isotope program, it is our perception that customers are satisfied with 
the quality of the isotope products that are provided for medical, industrial, and research applications. 
However, improvements could be made in the availability and timely supply of isotopes that are in 
demand for therapeutic medical applications and research (e.g., copper-67 and bismuth-212 for early- 
stage cancer therapy trials and laboratory animal research). 
2.0 What should be the long-term role of Government in providing commercial 
and research isotopes? 
Response: 
It is our firm belief that the supply of isotopes provided by DOE for medical, industrial, and research 
applications must be strengthened in the near future. This opinion is reinforced by the conclusions of a 
recent DOE Expert Panel Report on the future need for medical isotopes (Expert Panel 1999). Many of 
the radioisotopes currently used for medical diagnosis and therapy of cancer and other diseases are 
imported from Canada, Europe, and Asia. This situation places the control of isotope availability, quality, 
and pricing in the hands of non-U.S. suppliers. It is our opinion that the needs of the U.S. customers for 
isotopes and isotope products are not being adequately served, and that the DOE infrastructure and 
facilities devoted to the supply of these products must be improved. The need for greater U.S. capabilities 
to supply isotopes for medicine and research is one of the fundamental bases for our proposal to restart 
the FFTF as a national DOE resource. 
BUSINESS SENSITIVE 
Responses to the Second Set of Questions 
The second set of questions received on July 5, 1999, consisted of four questions to which responses 
are provided below. 
Detail how you set the price of a mCi of a radioisotope. 'The detail should 
show if the cost is fully loaded or incremental, and should include labor, 
materials and parts, facility rental and amortization costs, listing of all actual 
overhead charges, waste disposal, and all other costs that are tagged to the 
cost of producing, marketing, selling, and distributing of the product (e.g., 
customer service, distribution, and ordering). Illustrate the above question 
with examples for the following radioisotopes: 1-1 31,l-125, Pd-103, P-32, and 
several research radioisotopes. 
Response: 
[N.B.: The pages on which the response to the above question is presented are labeled as BUSINESS 
SENSITIVE to indicate the proprietary nature of the data that are displayed.] 
Prices are set by the Department of Energy's Isotope Programs Office (NE-70) using information 
provided by the Isotope Production Sites in the form of costlprice analyses for all isotope products. The 
Isotope Production Sites themselves do not set prices for the isotope products produced under the DOE 
contract. The pricing guidelines used by DOE are described in the annual financial statement, which is 
audited on a yearly basis by KPMG Peat Marwick. These guidelines state, in brief, that the prices are set 
on the basis of (1) actual production costs, (2) market value of the product, (3) needs of the research 
community for the product, and (4) other factors. 
In response to the NERAC subcommittee's question, costlprice analyses have been prepared for I- 
131,I-125, P-32 and Pd-103, as well as several isotopes that are currently in demand for research and 
early-stage clinical trials. The costlprice analyses were prepared in a format consistent with that used by 
DOE Isotope Production Sites, and the labor costs are fully burdened. The following are the overhead 
rates in FY 1999 applied to labor costs by PNNL and the Babcock & Wilcox Hanford Company 
(B WHC) : 
PNNL: G&A + Nuclear Assessment - 44.8% 
Program Development and Marketing - 6.0% 
Service Assessment - 1.0% 
BWHC: Project Management Account - 16.0% 
G&A + Service Assessment - 15.7% 
BUSINESS SENSITIVE 
In the cost/price analyses, the labor rates that are used assume that the target preparation, target 
insertion and retrieval, and irradiation services are performed by BWHC as a subcontractor organization, 
and the target processing and packaging are performed by PNNL. It is also assumed that PNNL manages 
the isotopes program office and handles customer sales and service functions. 
The following analysis of cost for producing isotopes of interest for research and medical applications 
is based on several assumptions: (1) the reactor is assumed to be in a steady-state mode of operation, with 
all equipment and operating procedures in place; (2) the target loading is designed to produce quantities of 
isotopes per operating cycle that could fill, on the average, about 10 to 20% of the projected U.S. market 
demand during the period 2005-2010; (3) the irradiation fee for each isotope product is based on the 
volume of space occupied by the target material in one or more assemblies; (4) all labor costs are fully 
burdened in accordance with the overhead rates presented above; (5) shipping of the isotope products is 
FOB Hanford; (6) a 12% added cost multiplier plus a 4% value recovery factor, or 16% total, is applied to 
the work done by the subcontractor on target fabrication, target testing and qualification, target irradiation, 
and target insertion and retrieval operations (to recover -$100M in costs associated with the reactor restart 
over a 35-year operating period as discussed under the response given above to Question 1.2 in the first set 
of questions). The cost analyses are performed per target assembly per operating cycle, which ranges from 
10 days to 100 days, depending upon the half-life of the isotope product. 
1 .I Four Isotope Products Requested by the NERAC Subcommittee 
Iodine-131 (tin = 8.0 days) is produced by irradiation of tellurium-130 targets in a hydrided rapid 
radioisotope retrieval (R3) assembly for 25 days. The iodine-13 1 product is separated from the 
tellurium target material by a dry distillation procedure (-400-500 OC in a tubular apparatus 
evacuated to -10.' rnrn) with cryogenic trapping of the iodine gas. The product is analyzed by 
inductively coupled plasma atomic emission spectroscopy (ICP-AES) for chemical purity, and by 
gamma energy analysis (GEA) for nuclide content. 
Table 1 summarizes the production cost per cycle for production of iodine-1 3 1. The product yield at 
the end of the 25-day cycle is 260 curies, with a production cost of $1.02 per millicurie. This cost 
compares favorably with the current market prices for radiochemically pure iodine-13 1, which range 
from $1 -50 to $15 .OO per millicurie (depending upon the supplier). 
As an example of the activity-based cost analysis that is the basis for the cumulative costs shown in 
Table 1, the cost estimates for target fabrication, testing and qualification, and insertion and retrieval 
at FFTF are shown in Table 2. The irradiation charge shown in Table 1 is based on the F'FlT 
business model that is described in detail in the FFI'F Scoping Plan (PNNL 1999b). 
Table 3 provides details for iodine-131 on the activity-based costing of the target processing, product 
packaging, and transport to the express mail carrier at a local airport. 
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Table 1. Summary of Costs for Production at F F I F  of Iodine-131 
Table 2. Target Fabrication and Testing Costs for Iodine-131 
FY99 Estimate 
STOl ETE Hours 
STOl Burdened FIT Cost 
STOl Burdened Material 
STOl Subcontract Cost 
STOl Other Cost 
1-131 GRAND TOTAL 
STOl 1-131 Targetry Cost 
$266,100 1 
Value Recovery & Added 
Cost Multipliers 
(a) Shipments are sent FOB Hanford 
(b) Based on number of curies at production. 
GRAND TOTAL 
BLSINESS SENSITIVE 
Table 3. Radiochemical Process ing ,  Packaging,  and Shipping Costs for Iodine-131 
STOl FIT Hours 
STOl Burdened FIX Cost 
STOl Burdened Material 
STOl Subcontract Cost 
STOl Other Cost 
STOl 1-131 Processing Cost 
Customer Sales & Service @ 8% 


















Iodine-125 (tin = 60.1 days) will be produced by irradiation of xenon-124 gas in a gas loop assembly 
for 100 days. The target gas is transmuted to xenon-125 (tin = 17.1 hr), which then decays to the 
iodine-125 product that is cryogenically trapped. The inert xenon target gas and the krypton gas used 
to push xenon through the gas line are distilled off, and the iodine-125 product is removed chemically 
from the wall of the cryotrap. The product is then analyzed for chemical purity and radionuclide 
content. The production costs for 43.3 curies of iodine-125 are shown in Table 4. The unit 
production cost is $14.63 per millicurie, which is within the range of market prices of $8 to $20 per 
millicurie for iodine- 125. 
Palladium-103 (tin = 17.0 days) will be produced by irradiation of palladium-102 in a hydrided R3 
assembly for 25 days. Following irradiation, the target material will be dissolved in nitric acid or 
aqua regia, evaporated to dryness, brought back into solution with the acid selected by the customer, 
and analyzed for chemical purity and radionuclide content. No separation will be made of the 
palladium-102 target material and the palladium-103 product. The production costs for 48 curies of 
palladium-103 are shown in Table 6. The unit production cost is $7.46 per millicurie, which is 
slightly below the market price of $9 to $12 per millicurie. 
Table 4. Summary of Costs for Production at FlTF of Iodine-125 
(a) Shipments are sent FOB Hanford. 
(b) Based on number of curies at production. 
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Table 5. Summary of Costs for Production at FI;TF of Palladium-103 
Table 6. Summary of Costs for Production at FFr'F of Phosphorus-32 
Production Total (STO1) $358500 48,000 $7.46 
Customer Sales & Service @ 8% of Processing Cost 
Pd-103 GRAND TOTAL 
(a) Shipments are sent FOB Hanford. 




Phosphorus-32 (tin = 14.3 days) is produced by irradiation of a sulfur-32 target in an R3 assembly for 
25 days. The product isotope is separated from the sulfur target material by dissolving the target in 
carbon disulfide and passing the solution through an activated carbon column. The column is then 
eluted with carbon disulfide to desorb the sulfur, dried, and eluted with warm (75 "C) nitric acid 
(5 M) to recover the phosphorus-32 product. The product is analyzed for chemical and nuclide 
purity. The production costs for 700 millicuries of phosphorus-32 are shown in Table 6. The unit 
production cost is $38.36 per millicurie, which is within the range of market prices of $25 to 
$85 per millicurie of phosphorus-32. 
1.2 Other Examples of Research Isotopes 
In this section of the report, cost analyses are presented for the production at FFTF of six isotopes that 
are of interest for cahcer therapy (e.g., copper-67, rhenium-186 and rhenium-188 derived from a tungsten- 
188 generator), bone pain palliation in patients with advanced metastatic bone cancer (e.g., strontium-89 
and tin-1 17m), and for calibration of gamma imaging systems (gadolinium-153). 
Copper47 (tin = 2.58 days) is produced by irradiating a zinc-67 oxide target in an R3 assembly for 
10 days. Following irradiation, the zinc oxide is dissolved in sulfuric acid, which is then placed in an 
electrochemical cell and the copper47 deposited on a platinum electrode. After 30 min. the solution 
containing zinc is removed and replaced with fresh acid solution, after which the copper deposition 
on the platinum electrode is continued for another 30 min. This procedure is repeated twice to ensure 
a high purity of the deposited copper-67. The platinum electrode is then removed and the deposited 
copper is dissolved by immersing the electrode in concentrated nitric acid. This solution is 
evaporated to dryness and the copper-67 product is then dissolved in an acid solution specified by 
the customer. The final product is analyzed for chemical purity and radionuclide content. The 
production costs for 1.85 curies of copper-67 are shown in Table 7. The unit production cost is 
$55.16 per millicurie, which compares favorably with the market price of $93 per millicurie. 
Gadolinium-153 (tin = 242 days) is produced by irradiation of natural europium-151/153 oxide pellets 
in a long-irradiation vehicle (LIV) for 100 days. Following irradiation, the target material is 
dissolved in acetic acid and the solution is contacted with granular zinc metal in an inert argon 
atmosphere to convert the europium (III) to europium (II). A sulfate salt is then added to precipitate 
the europium (11), thereby separating it from the gadolinium-153 product. This procedure is repeated 
three times, at which point the gadolinium-153 has the 99.999% level of purity required for its use 
as a calibration isotope. The purified gadolinium-153 is then subjected to oxalate precipitation, 
BUSINESS SENSITIVE 
Table 7. Summary of Costs for Production at FFTF of Copper-67 
followed by filtration and calcination to gadolinium oxide. These procedures are the subject of a 
U.S. patent application filed in August 1998. The final product is analyzed for chemical purity and 
radionuclide content. The production costs for 66 curies of gadolinium-153 are shown in Table 8. 
The unit production cost is $1.04 per millicurie, which compares favorably with the market price of 
$3.00 per millicurie. 
Rhenium-186 (tin = 3.78 days) is produced by irradiation of rhenium-185 in a hydrided R3 assembly 
for 25 days. Following irradiation, the target material is dissolved in nitric acid or aqua regia, 
evaporated to dryness, and redissolved in an acid specified by the customer. No effort is made to 
separate the rhenium-185 target material from the rhenium-186 product. The final product is 
analyzed for chemical purity and radionuclide content. The production costs for 15 curies of 
rhenium-186 are shown in Table 9. The unit production cost is $1.43 per millicurie, which'compares 
favorably with the market price of $7.00 per millicurie. 
Estimated Budget 
~ctivity'" 
Fabrication of Targets (ST01 01 01 0) 
Irradiation of Targets (ST0 101 020) 
Chemical Processing (ST0101040) 
Waste Management (ST0101 050) 
Quality Assurance (ST0101060) 
ES&H, Regulatory Compliance & Safety (ST0101070) 
Product Packaging (STOlOlO80) 
Program Management (ST01 01 090) 
Production Total (SW1) 
Customer Sales & Service @ 8% of Processing Cost 
01-67 GRAND TOTAL 
Tin-l17m (tin = 13.6 days) is produced by the irradiation of tin-116 in a hydrided R3 assembly for 
25 days. Following irradiation, the target material is dissolved in nitric acid or aqua regia, evaporated 
to dryness, and redissolved in an acid specified by the customer. No effort is made to separate the 
tin-116 target material from the tin-117m product. The product is analyzed for chemical purity and 
radionuclide content. The production costs for 1 curie of tin-l17m are shown in Table 10. The unit 
production cost is $29.75 per millicurie. 






















































BUSINESS SENSIT1 VE 
Table 8. Summary of Costs for Production at FE;TT; of Gadolinium-153 
Table 9. Summary of Costs for Production at FFTF of Rhenium-186 
Production Total (STOI) 
Customer Sales & Service @ 8% of Processing Cost 
GD-153 GRAND TOTAL 
(a) Shipments are sent FOB Hanford. 
(b) Based on number of curies at production. 
$206,700 
$6,000 
Production Total (STOI) 
Customer Sales & Service @ 8% of Processing Cost 




(a) Shipments are sent FOB Hanford. 










Table 10. Summary of Costs for Production at FFTF of Tin-1 17m 
Strontium-89 (tin = 50.5 days) is produced by irradiation of strontium-88 carbonate in a hydrided LIV 
assembly for 100 days. The strontium-89 is purified to remove traces of contaminants using a 
strontium-selective chromatographic resin (Sr-Spec). The column is rinsed with 3 M nitric acid to 
remove all elements other than strontium, and the strontium is then eluted with 0.3 M nitric acid. The 
final product is evaporated to dryness and then dissolved in an acid specified by the customer. No 
effort is made to separate the strontium-89 from other species of strontium contained in the final 
product. The final product is analyzed for chemical purity and radionuclide content. The production 
costs for 4.2 curies of strontium-89 are shown in Table 11. The unit production cost is $10.83 per 
millicurie, which compares favorably with the market price of $1 13 per millicurie. 
Tungsten-188 (tlR = 69.4 days) is produced by irradiation of tungsten 186 in a hydrided LIV assembly 
for 100 days. The primary use of the tungsten-188 is as a generator material for the rhenium-188 
decay product. The target is dissolved in nitric acid or aqua regia, evaporated to dryness, and 
redissolved in an acid specified by the customer. No effort is made to separate the tungsten-186 
target from the tungsten-188 product. The final product is analyzed for chemical purity and 
radionuclide content. The production costs for 11 curies of tungsten-188 are shown in Table 12. The 
unit production cost is $12.86 per millicurie, which is higher than the current market price of $4 to 
$5 per millicurie. 
Estimated Budget 
~ctivit~'.' 
Fabrication of Targets (ST0101010) 
Irradiation of Targets (ST01 01 020) 
Chemical Processing (ST0101040) 
Waste Management (ST01 01050) 
Quality Assurance (ST0101060) 
ES&H, Regulatory Compliance & Safety (ST0101070) 
Product Packaging (ST010 1080) 
Program Management (ST0101 090) 
Production Total (STOl) 
Customer Sales & Service @ 8% of Processing Cost 
Sn-ll7m GRAND TOTAL 






















































Table 11. Summary of Costs for Production at FFTF of Strontium-89 
Table 12. Summary of Costs for Production at FlTF of Tungsten-188 
Estimated Budget 
Activity"' 
Fabrication of Targets (ST0101 010) 
Irradiation of Targets (ST01 01 020) 
Chemical Processing (ST01 01040) 
Waste Management (ST0101 050) 
Quality Assurance (ST0101060) 
ES&H, Regulatory Compliance & Safety (ST0101070) 
Product Packaging (ST01 01 080) 
Program Management (ST0101090) 
Production Total (STOI) 
Customer Sales & Service @ 8% of Processing Cost 
Sr-89 GRAND TOTAL 










































Fabrication of Targets (ST01 01010) 
Irradiation of Targets (ST01 01 020) 
Chemical Processing (ST01 01040) 
Waste Management (ST0101050) 
Quality Assurance (ST0101 060) 
ES&H, Regulatory Compliance & Safety (ST0101070) 
Product Packaging (ST0101080) 
Program Management (ST01 01 090) 
Production Total (STOI) 
Customer Sales & Senice @ 8% of Processing Cost 
W-188 Grand Total 



































































2.0 What process, mechanism, and organizational structure do you have for the 
timely distribution of the produced product? 
Response: 
Packaging and distribution of isotope products are directly coupled to the isotope production process. 
Upon preparation of a vial of isotope to the specifications provided by a customer, the vial is transferred 
into a lead container (pig) with an overpack and taken to an adjacent laboratory. A member of the PNNL 
isotope production team then packages the pig into a labeled, DOT-approved container and inserts 
customer-specific data. An offsite Radioactive Shipment Record and other paperwork required by the 
Department of Transportation are attached to the drum and it is taken to the Richland airport (a distance 
of about 2 miles) for shipment by Airborne Express to the customer. In addition to Airborne Express, 
other major express mail carriers such as Federal Express have offices at the three airports located within 
a 15-mile radius of the Hanford Site, and are used for shipping of isotopes to some international locations. 
The overall time that elapses between preparation of the customer vial and its delivery to the express mail 
carrier is typically 2 to 4 hours. 
A detailed flowchart showing all of the activities involved in the packaging and shipping of an 
isotope product is presented in PNNL (1999a) (Section 2.6.1). PNNL has contracts with two 
subcontractors that assist with the shipping of isotopes: (1) DynCorp transports isotope samples from the 
production laboratory at the RPL to the 222s Building for ICP analysis, and (2) Waste Management 
Federal Services transports the isotope shipping containers from the RPL to the airport for delivery to the 
express mail carrier. All containers that are sent to customers contain A-type quantities of isotopes to 
minimize shielding requirements and avoid delays in isotope delivery. Shipments are made FOB 
Hanford, and the customer pays the costs of express mail shipping. In general, the record of Airborne 
Express and other carriers has been very good, with an average on-time delivery record of 98% for more 
than 1200 shipments over the past two years. 
3.0 What process, mechanism, and organizational structure do you have for 
customer service? 
Response: 
The customer sales and service functions are conducted as part of the Hanford Radioisotopes Program 
at a total level of effort of 1.5 FTE. Customer orders are taken by telephone, E-mail, or FAX and 
compiled into a spreadsheet that forms the basis for the. weekly isotope production campaign. Care is 
taken to note all customer-specific ordering information, and to compile all of the necessary paperwork 
such as a copy of the customer's radioactive materials license in advance of shipping (to ensure that the 
customer can receive the shipment). The sales and service staff also work with PNNL and Waste 
Management Federal Services transportation specialists to identify the most efficient shipping routes and 
air carriers for international orders (about 50% of the total isotope sales in 1997-1999). Speiial efforts are 
made to accommodate special requests, especially when the isotope is required for the treatment of 
critically ill cancer patients. The response time under those circumstances can be as little as a few hours. 
Approximately 350 special requests have been met successfully over the past 10 years. 
If FFTF undertakes isotope production in 2004, it is expected that the customer sales and service 
functions will be increased at that time to a level of effort of approximately 5.5 FTE. In addition, 
opportunities for privatization of this component of the isotopes program are being explored through 
ongoing discussions with commercial companies. 
4.0 Will you sign contracts that guarantee delivery at the contracted time of 
delivery, and where the contract has penalty clauses for untimely delivery of 
the specified product? 
Response: 
PNNL supplies isotopes under a standard DOE customer service agreement, and handles invoicing 
and all other aspects of each sales transaction. All isotope products are shipped FOB Hanford, and 
become the responsibility of the customer at the time of shipment. Accordingly, our service contracts do 
not have penalty clauses for untimely delivery by the express mail carrier. However, in practice we have 
routinely waived all charges if the delivery of an isotope product is delayed and the customer is unable to 
use it. This waiver of charges is subject to DOE approval, but the Isotope Progams Office (NE-70) staff 
have consistently permitted a waiver to be made under reasonable circumstances. In our opinion, this 
practice is more "customer friendly" than introducing a penalty clause for untimely delivery in the 
customer service contract. 
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